APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia Drugs

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hemophilia Drugs Market Analysis and Forecast 2026-2032

22 December 2025194 pages

Choose your research edition.

Industry ResearchHemophilia Drugs Industry Research Report 2026123 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia Drugs Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Hemophilia Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia Drugs Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia Drugs Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Hemophilia Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hemophilia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hemophilia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hemophilia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hemophilia Drugs is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hemophilia Drugs include Pfizer, Bayer, Swedish Orphan Biovitrum, Spark Therapeutics, Sangamo Biosciences, Octapharma, Grifols, F. Hoffmann-La Roche and Dimension Therapeutics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hemophilia Drugs, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hemophilia Drugs, also provides the revenue of main regions and countries. Of the upcoming market potential for Hemophilia Drugs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hemophilia Drugs revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hemophilia Drugs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hemophilia Drugs revenue, projected growth trends, production technology, application and end-user industry.

Hemophilia Drugs Segment by Company

Pfizer

Bayer

Swedish Orphan Biovitrum

Spark Therapeutics

Sangamo Biosciences

Octapharma

Grifols

F. Hoffmann-La Roche

Dimension Therapeutics

CSL Behring

Catalyst Biosciences

BioMarin

Baxalta

Alnylam Pharmaceuticals

Hemophilia Drugs Segment by Type

Von Willebrand Disease

Hemophilia A

Hemophilia B

Inhibitors

Hemophilia Drugs Segment by Application

Recombinant Therapies

Plasma-Derived Therapies

Hemophilia Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hemophilia Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hemophilia Drugs company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hemophilia Drugs revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hemophilia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Von Willebrand Disease Major Player Table 3. Hemophilia A Major Player Table 4. Hemophilia B Major Player Table 5. Inhibitors Major Player Table 6. Global Hemophilia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Recombinant Therapies Major Player Table 8. Plasma-Derived Therapies Major Player Table 9. Hemophilia Drugs Industry Trends Table 10. Hemophilia Drugs Industry Drivers Table 11. Hemophilia Drugs Industry Opportunities and Challenges Table 12. Hemophilia Drugs Industry Restraints Table 13. Global Hemophilia Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Hemophilia Drugs Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Hemophilia Drugs Market Share by Region (2021-2026) Table 16. Global Hemophilia Drugs Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Hemophilia Drugs Market Share by Region (2027-2032) Table 18. Global Hemophilia Drugs Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Hemophilia Drugs Revenue Market Share by Players (2021-2026) Table 20. Global Hemophilia Drugs Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Hemophilia Drugs Key Players Headquarters & Area Served Table 22. Global Hemophilia Drugs Players, Product Type & Application Table 23. Global Hemophilia Drugs Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Hemophilia Drugs by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Hemophilia Drugs Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Hemophilia Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Hemophilia Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Hemophilia Drugs Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Hemophilia Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Hemophilia Drugs Revenue Market Share by Application (2027-2032) Table 36. Pfizer Company Information Table 37. Pfizer Business Overview Table 38. Pfizer Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Pfizer Hemophilia Drugs Product Portfolio Table 40. Pfizer Recent Development Table 41. Bayer Company Information Table 42. Bayer Business Overview Table 43. Bayer Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Bayer Hemophilia Drugs Product Portfolio Table 45. Bayer Recent Development Table 46. Swedish Orphan Biovitrum Company Information Table 47. Swedish Orphan Biovitrum Business Overview Table 48. Swedish Orphan Biovitrum Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio Table 50. Swedish Orphan Biovitrum Recent Development Table 51. Spark Therapeutics Company Information Table 52. Spark Therapeutics Business Overview Table 53. Spark Therapeutics Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Spark Therapeutics Hemophilia Drugs Product Portfolio Table 55. Spark Therapeutics Recent Development Table 56. Sangamo Biosciences Company Information Table 57. Sangamo Biosciences Business Overview Table 58. Sangamo Biosciences Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Sangamo Biosciences Hemophilia Drugs Product Portfolio Table 60. Sangamo Biosciences Recent Development Table 61. Octapharma Company Information Table 62. Octapharma Business Overview Table 63. Octapharma Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Octapharma Hemophilia Drugs Product Portfolio Table 65. Octapharma Recent Development Table 66. Grifols Company Information Table 67. Grifols Business Overview Table 68. Grifols Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Grifols Hemophilia Drugs Product Portfolio Table 70. Grifols Recent Development Table 71. F. Hoffmann-La Roche Company Information Table 72. F. Hoffmann-La Roche Business Overview Table 73. F. Hoffmann-La Roche Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio Table 75. F. Hoffmann-La Roche Recent Development Table 76. Dimension Therapeutics Company Information Table 77. Dimension Therapeutics Business Overview Table 78. Dimension Therapeutics Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Dimension Therapeutics Hemophilia Drugs Product Portfolio Table 80. Dimension Therapeutics Recent Development Table 81. CSL Behring Company Information Table 82. CSL Behring Business Overview Table 83. CSL Behring Hemophilia Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. CSL Behring Hemophilia Drugs Product Portfolio Table 85. CSL Behring Recent Development Table 86. Catalyst Biosciences Company Information Table 87. Catalyst Biosciences Business Overview Table 88. Catalyst Biosciences Hemophilia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 89. Catalyst Biosciences Hemophilia Drugs Product Portfolio Table 90. Catalyst Biosciences Recent Development Table 91. BioMarin Company Information Table 92. BioMarin Business Overview Table 93. BioMarin Hemophilia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 94. BioMarin Hemophilia Drugs Product Portfolio Table 95. BioMarin Recent Development Table 96. Baxalta Company Information Table 97. Baxalta Business Overview Table 98. Baxalta Hemophilia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 99. Baxalta Hemophilia Drugs Product Portfolio Table 100. Baxalta Recent Development Table 101. Alnylam Pharmaceuticals Company Information Table 102. Alnylam Pharmaceuticals Business Overview Table 103. Alnylam Pharmaceuticals Hemophilia Drugs Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 104. Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio Table 105. Alnylam Pharmaceuticals Recent Development Table 106. North America Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 107. North America Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 108. North America Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 111. North America Hemophilia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 112. North America Hemophilia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 113. Europe Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 114. Europe Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 115. Europe Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 116. Europe Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 117. Europe Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Europe Hemophilia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 119. Europe Hemophilia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 120. China Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 121. China Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 122. China Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 123. China Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 124. Asia Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 125. Asia Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 126. Asia Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 127. Asia Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 128. Asia Hemophilia Drugs Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 129. Asia Hemophilia Drugs Revenue by Region (US$ Million) & (2021-2026) Table 130. Asia Hemophilia Drugs Revenue by Region (US$ Million) & (2027-2032) Table 131. SAMEA Hemophilia Drugs Revenue by Type (2021-2026) & (US$ Million) Table 132. SAMEA Hemophilia Drugs Revenue by Type (2027-2032) & (US$ Million) Table 133. SAMEA Hemophilia Drugs Revenue by Application (2021-2026) & (US$ Million) Table 134. SAMEA Hemophilia Drugs Revenue by Application (2027-2032) & (US$ Million) Table 135. SAMEA Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 136. SAMEA Hemophilia Drugs Revenue by Country (2021-2026) & (US$ Million) Table 137. SAMEA Hemophilia Drugs Revenue by Country (US$ Million) & (2027-2032) Table 138. Research Programs/Design for This Report Table 139. Authors List of This Report Table 140. Secondary Sources Table 141. Primary Sources List of Figures Figure 1. Hemophilia Drugs Image Figure 2. Global Hemophilia Drugs Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 4. Von Willebrand Disease Image Figure 5. Hemophilia A Image Figure 6. Hemophilia B Image Figure 7. Inhibitors Image Figure 8. Global Hemophilia Drugs Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Hemophilia Drugs Market Size Share 2021 VS 2025 VS 2032 Figure 10. Recombinant Therapies Image Figure 11. Plasma-Derived Therapies Image Figure 12. Global Hemophilia Drugs Market Size (US$ Million) & (2021-2032) Figure 13. Global Hemophilia Drugs Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Hemophilia Drugs Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Hemophilia Drugs Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Hemophilia Drugs Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Hemophilia Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Hemophilia Drugs Revenue Market Share by Type (2021-2032) Figure 20. Global Hemophilia Drugs Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Hemophilia Drugs Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Hemophilia Drugs Revenue Market Share by Application (2021-2032) Figure 23. North America Hemophilia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Hemophilia Drugs Revenue Share by Type (2021-2032) Figure 25. North America Hemophilia Drugs Revenue Share by Application (2021-2032) Figure 26. North America Hemophilia Drugs Revenue Share by Country (2021-2032) Figure 27. United States Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Hemophilia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Hemophilia Drugs Revenue Share by Type (2021-2032) Figure 32. Europe Hemophilia Drugs Revenue Share by Application (2021-2032) Figure 33. Europe Hemophilia Drugs Revenue Share by Country (2021-2032) Figure 34. Germany Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Hemophilia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Hemophilia Drugs Revenue Share by Type (2021-2032) Figure 44. China Hemophilia Drugs Revenue Share by Application (2021-2032) Figure 45. Asia Hemophilia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Hemophilia Drugs Revenue Share by Type (2021-2032) Figure 47. Asia Hemophilia Drugs Revenue Share by Application (2021-2032) Figure 48. Asia Hemophilia Drugs Revenue Share by Region (2021-2032) Figure 49. Japan Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Hemophilia Drugs Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Hemophilia Drugs Revenue Share by Type (2021-2032) Figure 57. SAMEA Hemophilia Drugs Revenue Share by Application (2021-2032) Figure 58. SAMEA Hemophilia Drugs Revenue Share by Country (2021-2032) Figure 59. Brazil Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Hemophilia Drugs Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Von Willebrand Disease
  • Hemophilia A
  • Hemophilia B
  • Inhibitors
Applications
  • Recombinant Therapies
  • Plasma-Derived Therapies
Companies covered
  • Pfizer
  • Bayer
  • Swedish Orphan Biovitrum
  • Spark Therapeutics
  • Sangamo Biosciences
  • Octapharma
  • Grifols
  • F. Hoffmann-La Roche
  • Dimension Therapeutics
  • CSL Behring
  • Catalyst Biosciences
  • BioMarin
  • Baxalta
  • Alnylam Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hemophilia Drugs Market by Type
  3. 1.2.1 Global Hemophilia Drugs Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Von Willebrand Disease
  5. 1.2.3 Hemophilia A
  6. 1.2.4 Hemophilia B
  7. 1.2.5 Inhibitors
  8. 1.3 Hemophilia Drugs Market by Application
  9. 1.3.1 Global Hemophilia Drugs Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Recombinant Therapies
  11. 1.3.3 Plasma-Derived Therapies
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Hemophilia Drugs Market Dynamics
  1. 2.1 Hemophilia Drugs Industry Trends
  2. 2.2 Hemophilia Drugs Industry Drivers
  3. 2.3 Hemophilia Drugs Industry Opportunities and Challenges
  4. 2.4 Hemophilia Drugs Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hemophilia Drugs Market Perspective (2021-2032)
  2. 3.2 Global Hemophilia Drugs Growth Trends by Region
  3. 3.2.1 Global Hemophilia Drugs Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hemophilia Drugs Market Size by Region (2021-2026)
  5. 3.2.3 Global Hemophilia Drugs Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hemophilia Drugs Revenue by Players
  2. 4.1.1 Global Hemophilia Drugs Revenue by Players (2021-2026)
  3. 4.1.2 Global Hemophilia Drugs Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hemophilia Drugs Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hemophilia Drugs Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hemophilia Drugs Key Players Headquarters & Area Served
  7. 4.4 Global Hemophilia Drugs Players, Product Type & Application
  8. 4.5 Global Hemophilia Drugs Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hemophilia Drugs Market CR5 and HHI
  11. 4.6.3 2025 Hemophilia Drugs Tier 1, Tier 2, and Tier 3
5 Hemophilia Drugs Market Size by Type
  1. 5.1 Global Hemophilia Drugs Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hemophilia Drugs Revenue by Type (2021-2032)
  3. 5.3 Global Hemophilia Drugs Revenue Market Share by Type (2021-2032)
6 Hemophilia Drugs Market Size by Application
  1. 6.1 Global Hemophilia Drugs Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hemophilia Drugs Revenue by Application (2021-2032)
  3. 6.3 Global Hemophilia Drugs Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Pfizer
  2. 7.1.1 Pfizer Company Information
  3. 7.1.2 Pfizer Business Overview
  4. 7.1.3 Pfizer Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Pfizer Hemophilia Drugs Product Portfolio
  6. 7.1.5 Pfizer Recent Developments
  7. 7.2 Bayer
  8. 7.2.1 Bayer Company Information
  9. 7.2.2 Bayer Business Overview
  10. 7.2.3 Bayer Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Bayer Hemophilia Drugs Product Portfolio
  12. 7.2.5 Bayer Recent Developments
  13. 7.3 Swedish Orphan Biovitrum
  14. 7.3.1 Swedish Orphan Biovitrum Company Information
  15. 7.3.2 Swedish Orphan Biovitrum Business Overview
  16. 7.3.3 Swedish Orphan Biovitrum Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Swedish Orphan Biovitrum Hemophilia Drugs Product Portfolio
  18. 7.3.5 Swedish Orphan Biovitrum Recent Developments
  19. 7.4 Spark Therapeutics
  20. 7.4.1 Spark Therapeutics Company Information
  21. 7.4.2 Spark Therapeutics Business Overview
  22. 7.4.3 Spark Therapeutics Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Spark Therapeutics Hemophilia Drugs Product Portfolio
  24. 7.4.5 Spark Therapeutics Recent Developments
  25. 7.5 Sangamo Biosciences
  26. 7.5.1 Sangamo Biosciences Company Information
  27. 7.5.2 Sangamo Biosciences Business Overview
  28. 7.5.3 Sangamo Biosciences Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Sangamo Biosciences Hemophilia Drugs Product Portfolio
  30. 7.5.5 Sangamo Biosciences Recent Developments
  31. 7.6 Octapharma
  32. 7.6.1 Octapharma Company Information
  33. 7.6.2 Octapharma Business Overview
  34. 7.6.3 Octapharma Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Octapharma Hemophilia Drugs Product Portfolio
  36. 7.6.5 Octapharma Recent Developments
  37. 7.7 Grifols
  38. 7.7.1 Grifols Company Information
  39. 7.7.2 Grifols Business Overview
  40. 7.7.3 Grifols Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Grifols Hemophilia Drugs Product Portfolio
  42. 7.7.5 Grifols Recent Developments
  43. 7.8 F. Hoffmann-La Roche
  44. 7.8.1 F. Hoffmann-La Roche Company Information
  45. 7.8.2 F. Hoffmann-La Roche Business Overview
  46. 7.8.3 F. Hoffmann-La Roche Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  47. 7.8.4 F. Hoffmann-La Roche Hemophilia Drugs Product Portfolio
  48. 7.8.5 F. Hoffmann-La Roche Recent Developments
  49. 7.9 Dimension Therapeutics
  50. 7.9.1 Dimension Therapeutics Company Information
  51. 7.9.2 Dimension Therapeutics Business Overview
  52. 7.9.3 Dimension Therapeutics Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Dimension Therapeutics Hemophilia Drugs Product Portfolio
  54. 7.9.5 Dimension Therapeutics Recent Developments
  55. 7.10 CSL Behring
  56. 7.10.1 CSL Behring Company Information
  57. 7.10.2 CSL Behring Business Overview
  58. 7.10.3 CSL Behring Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  59. 7.10.4 CSL Behring Hemophilia Drugs Product Portfolio
  60. 7.10.5 CSL Behring Recent Developments
  61. 7.11 Catalyst Biosciences
  62. 7.11.1 Catalyst Biosciences Company Information
  63. 7.11.2 Catalyst Biosciences Business Overview
  64. 7.11.3 Catalyst Biosciences Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Catalyst Biosciences Hemophilia Drugs Product Portfolio
  66. 7.11.5 Catalyst Biosciences Recent Developments
  67. 7.12 BioMarin
  68. 7.12.1 BioMarin Company Information
  69. 7.12.2 BioMarin Business Overview
  70. 7.12.3 BioMarin Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  71. 7.12.4 BioMarin Hemophilia Drugs Product Portfolio
  72. 7.12.5 BioMarin Recent Developments
  73. 7.13 Baxalta
  74. 7.13.1 Baxalta Company Information
  75. 7.13.2 Baxalta Business Overview
  76. 7.13.3 Baxalta Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Baxalta Hemophilia Drugs Product Portfolio
  78. 7.13.5 Baxalta Recent Developments
  79. 7.14 Alnylam Pharmaceuticals
  80. 7.14.1 Alnylam Pharmaceuticals Company Information
  81. 7.14.2 Alnylam Pharmaceuticals Business Overview
  82. 7.14.3 Alnylam Pharmaceuticals Hemophilia Drugs Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Alnylam Pharmaceuticals Hemophilia Drugs Product Portfolio
  84. 7.14.5 Alnylam Pharmaceuticals Recent Developments
8 North America
  1. 8.1 North America Hemophilia Drugs Revenue (2021-2032)
  2. 8.2 North America Hemophilia Drugs Revenue by Type (2021-2032)
  3. 8.2.1 North America Hemophilia Drugs Revenue by Type (2021-2026)
  4. 8.2.2 North America Hemophilia Drugs Revenue by Type (2027-2032)
  5. 8.3 North America Hemophilia Drugs Revenue Share by Type (2021-2032)
  6. 8.4 North America Hemophilia Drugs Revenue by Application (2021-2032)
  7. 8.4.1 North America Hemophilia Drugs Revenue by Application (2021-2026)
  8. 8.4.2 North America Hemophilia Drugs Revenue by Application (2027-2032)
  9. 8.5 North America Hemophilia Drugs Revenue Share by Application (2021-2032)
  10. 8.6 North America Hemophilia Drugs Revenue by Country
  11. 8.6.1 North America Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hemophilia Drugs Revenue by Country (2021-2026)
  13. 8.6.3 North America Hemophilia Drugs Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Hemophilia Drugs Revenue (2021-2032)
  2. 9.2 Europe Hemophilia Drugs Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hemophilia Drugs Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hemophilia Drugs Revenue by Type (2027-2032)
  5. 9.3 Europe Hemophilia Drugs Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hemophilia Drugs Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hemophilia Drugs Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hemophilia Drugs Revenue by Application (2027-2032)
  9. 9.5 Europe Hemophilia Drugs Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hemophilia Drugs Revenue by Country
  11. 9.6.1 Europe Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hemophilia Drugs Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hemophilia Drugs Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Hemophilia Drugs Revenue (2021-2032)
  2. 10.2 China Hemophilia Drugs Revenue by Type (2021-2032)
  3. 10.2.1 China Hemophilia Drugs Revenue by Type (2021-2026)
  4. 10.2.2 China Hemophilia Drugs Revenue by Type (2027-2032)
  5. 10.3 China Hemophilia Drugs Revenue Share by Type (2021-2032)
  6. 10.4 China Hemophilia Drugs Revenue by Application (2021-2032)
  7. 10.4.1 China Hemophilia Drugs Revenue by Application (2021-2026)
  8. 10.4.2 China Hemophilia Drugs Revenue by Application (2027-2032)
  9. 10.5 China Hemophilia Drugs Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hemophilia Drugs Revenue (2021-2032)
  2. 11.2 Asia Hemophilia Drugs Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hemophilia Drugs Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hemophilia Drugs Revenue by Type (2027-2032)
  5. 11.3 Asia Hemophilia Drugs Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hemophilia Drugs Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hemophilia Drugs Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hemophilia Drugs Revenue by Application (2027-2032)
  9. 11.5 Asia Hemophilia Drugs Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hemophilia Drugs Revenue by Country
  11. 11.6.1 Asia Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hemophilia Drugs Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hemophilia Drugs Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hemophilia Drugs Revenue (2021-2032)
  2. 12.2 SAMEA Hemophilia Drugs Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hemophilia Drugs Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hemophilia Drugs Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hemophilia Drugs Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hemophilia Drugs Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hemophilia Drugs Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hemophilia Drugs Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hemophilia Drugs Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hemophilia Drugs Revenue by Country
  11. 12.6.1 SAMEA Hemophilia Drugs Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hemophilia Drugs Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hemophilia Drugs Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst